These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 11059631

  • 1. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 2. Improving Antihypertensive Efficacy while Maintaining Placebo-like Tolerability.
    Sever PS.
    Blood Press; 2000; 9(sup1):19-22. PubMed ID: 28425798
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

  • 4. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 5. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 6. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P.
    Blood Press Suppl; 2000 May 11; 1():23-6. PubMed ID: 11059632
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr 11; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT, O'Kane KP, Jonker J, Roth J.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [Abstract] [Full Text] [Related]

  • 9. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F.
    Blood Press Suppl; 2000 Sep 11; 1():36-9. PubMed ID: 11059635
    [Abstract] [Full Text] [Related]

  • 10. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec 11; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]

  • 11. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
    Ruilope L.
    Blood Press Suppl; 2000 Dec 11; 1():31-5. PubMed ID: 11059634
    [Abstract] [Full Text] [Related]

  • 12. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM.
    Int J Clin Pract; 2006 Apr 11; 60(4):391-8. PubMed ID: 16620350
    [Abstract] [Full Text] [Related]

  • 13. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
    Sever PS.
    J Hum Hypertens; 1999 Jan 11; 13 Suppl 1():S3-10; discussion S33-4. PubMed ID: 10076915
    [Abstract] [Full Text] [Related]

  • 14. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec 11; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 15. Reducing cardiovascular morbidity and mortality in the elderly.
    Trenkwalder P.
    Blood Press Suppl; 2000 Dec 11; 1():40-3. PubMed ID: 11059636
    [Abstract] [Full Text] [Related]

  • 16. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
    Unger T.
    Blood Press Suppl; 2000 Dec 11; 1():14-8. PubMed ID: 11059630
    [Abstract] [Full Text] [Related]

  • 17. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
    Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, Cushing DJ, Michelson EL.
    Am J Cardiol; 1998 Oct 15; 82(8):961-5. PubMed ID: 9794352
    [Abstract] [Full Text] [Related]

  • 18. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
    Oparil S, Levine JH, Zuschke CA, Gradman AH, Ripley E, Jones DW, Hardison JD, Cushing DJ, Prasad R, Michelson EL.
    Am J Cardiol; 1999 Aug 01; 84(3):289-93. PubMed ID: 10496437
    [Abstract] [Full Text] [Related]

  • 19. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B, Gerwe M, Braun M, Funken C.
    Arzneimittelforschung; 2005 Aug 01; 55(9):505-13. PubMed ID: 16229114
    [Abstract] [Full Text] [Related]

  • 20. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK, Neldam S.
    Blood Press; 1998 Jan 01; 7(1):53-9. PubMed ID: 9551878
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.